Anteris Technologies Global Corp. (NASDAQ:AVR) Stock Rated "Hold" by Sell-Side Analysts

Key Points

• Analysts have a consensus “Hold” rating on Anteris Technologies Global, with three buys, one hold and one sell among five analysts. The average 12-month price target is $14, compared with the stock’s recent price of $6.77.
• Financial performance remains weak: the company reported a quarterly loss of $0.30 per share versus the expected $0.21 loss, while revenue of $1.01 million missed the $1.50 million estimate. Analysts expect a full-year loss of approximately $1.21 per share.
• Investor sentiment is mixed. Major shareholder L1 Capital increased its stake through substantial purchases, and several institutions added positions, but potential employee-plan dilution and the company’s continued unprofitability remain key risks.

Anteris Technologies Global Corp. (NASDAQ:AVR - Get Free Report) has been given an average recommendation of "Hold" by the five ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $14.00.

A number of equities analysts have recently commented on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research report on Friday, August 14th. Barclays raised shares of Anteris Technologies Global to a "hold" rating in a report on Wednesday, October 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th.

Anteris Technologies Global Price Performance

Shares of NASDAQ AVR opened at $6.77 on Monday. The stock's 50-day moving average is $8.39 and its two-hundred day moving average is $8.03. Anteris Technologies Global has a 1-year low of $3.30 and a 1-year high of $11.06. The company has a market cap of $659.80 million, a price-to-earnings ratio of -3.47 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.09). The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period in the prior year, the business earned ($0.58) EPS. Equities research analysts anticipate that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

More Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: L1 Capital expanded its AVR stake. The major shareholder purchased 272,695 shares for approximately $1.96 million at an average price of $7.18, increasing its position by 4.48% to 6.36 million shares. The purchase follows additional buying totaling more than 1.2 million shares in early October, signaling continued confidence from a significant investor. SEC filing on L1 Capital’s AVR purchase
• Positive Sentiment: Institutional ownership has grown. BlackRock, ADAR1 Capital Management, Bank of New York Mellon and other investment firms recently established or increased positions in AVR. Such buying may improve investor sentiment and provide additional institutional support, although the positions were reported from earlier quarters.
• Neutral Sentiment: Barclays initiated coverage at Hold/Equal Weight. The rating gives AVR additional analyst visibility but indicates limited conviction for near-term outperformance. Other analysts remain divided, with an average rating of Hold and an average price target of $14. Barclays AVR rating report
• Neutral Sentiment: Short-interest data showed no current short position. The latest report listed short interest at zero shares and a zero-day days-to-cover ratio. This does not indicate meaningful short-squeeze potential, though the figure may reflect a reporting or data-timing issue.
• Negative Sentiment: Employee equity-plan expansion could create dilution concerns. Anteris expanded unquoted equity under its employee incentive plan. Potential future share issuance may weigh on the stock, particularly because the clinical-stage company remains unprofitable. Anteris employee incentive-plan announcement
• Negative Sentiment: Financial results remain weak. Anteris recently reported a larger-than-expected quarterly loss and revenue below forecasts. Analysts expect a full-year loss, keeping execution, clinical progress and future financing as key risks.

Insider Buying and Selling

In other news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the company's stock in a transaction on Monday, October 5th. The shares were bought at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the transaction, the insider owned 12,778,380 shares in the company, valued at approximately $95,965,633.80. This trade represents a 5.35% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have purchased 1,554,730 shares of company stock worth $11,694,513 and have sold 3,008,459 shares worth $25,243,576. 4.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Anteris Technologies Global

A number of hedge funds and other institutional investors have recently modified their holdings of AVR. Legal & General Group Plc acquired a new position in shares of Anteris Technologies Global during the second quarter worth $78,000. Abel Hall LLC purchased a new position in Anteris Technologies Global in the first quarter valued at $63,000. Bartlett & CO. Wealth Management LLC raised its stake in Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company's stock valued at $79,000 after buying an additional 8,200 shares in the last quarter. One68 Global Capital LLC acquired a new stake in Anteris Technologies Global in the second quarter valued at $128,000. Finally, J. Derek Lewis & Associates Inc. acquired a new stake in Anteris Technologies Global in the fourth quarter valued at $70,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.